Development of an intranasal formulation containing indomethacin and xylometazoline for rhinosinusitis treatment.

Kar M., Ince I., Yildirim C., Burukoğlu Dönmez D., Karasulu Y., Cingi C.

European review for medical and pharmacological sciences, cilt.26, sa.2 Suppl, ss.65-71, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2 Suppl
  • Basım Tarihi: 2022
  • Doi Numarası: 10.26355/eurrev_202212_30486
  • Dergi Adı: European review for medical and pharmacological sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.65-71
  • Anahtar Kelimeler: Xylometazoline, Indomethacin, Intranasal Formulation, PERMEATION
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

OBJECTIVE: Use of the nasal route of drug administration dates back many years and is used both to achieve topical treatments and to allow systemic absorption. The objective was to develop a formulation with novel features which enhance prolonged contact with the nasal and sinusal lining, since this should increase any therapeutic benefit. The anti-inflammatory drug selected was indomethacin, which was combined with xylometazoline, an effective nasal decongestant agent.